Literature DB >> 19687358

Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability.

Stefanie Seehaus1, Khurrum Shahzad, Muhammed Kashif, Ilya A Vinnikov, Martin Schiller, Hongjie Wang, Thati Madhusudhan, Volker Eckstein, Angelika Bierhaus, Florian Bea, Erwin Blessing, Hartmut Weiler, David Frommhold, Peter P Nawroth, Berend Isermann.   

Abstract

BACKGROUND: Clinical studies failed to provide clear evidence for a proatherogenic role of hypercoagulability. This is in contrast to the well-established detrimental role of hypercoagulability and thrombin during acute atherosclerotic complications. These seemingly opposing data suggest that hypercoagulability might exert both proatherogenic and antiatherogenic effects. We therefore investigated whether hypercoagulability mediates a beneficial effect during de novo atherogenesis. METHODS AND
RESULTS: De novo atherogenesis was evaluated in 2 mouse models with hyperlipidemia and genetically imposed hypercoagulability (TM(Pro/Pro)ApoE(-/-) and FVL(Q/Q)ApoE(-/-) mice). In both mouse models, hypercoagulability resulted in larger plaques, but vascular stenosis was not enhanced secondary to positive vascular remodeling. Importantly, plaque stability was increased in hypercoagulable mice with less necrotic cores, more extracellular matrix, more smooth muscle cells, and fewer macrophages. Long-term anticoagulation reversed these changes. The reduced frequency of intraplaque macrophages in hypercoagulable mice is explained by an inhibitory role of thrombin and protease-activated receptor-1 on monocyte transendothelial migration in vitro. This is dependent on phospholipase-Cbeta, phosphoinositide 3-kinase, and nitric oxide signaling in monocytes but not in endothelial cells.
CONCLUSIONS: Here, we show a new function of the coagulation system, averting stenosis and plaque destabilization during de novo atherogenesis. The in vivo and in vitro data establish that thrombin-induced signaling via protease-activated receptor-1, phospholipase-Cbeta, phosphoinositide 3-kinase, and nitric oxide in monocytes impairs monocyte transendothelial migration. This likely accounts for the reduced macrophage accumulation in plaques of hypercoagulable mice. Thus, in contrast to their role in unstable plaques or after vascular injury, hypercoagulability and thrombin convey a protective effect during de novo atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687358     DOI: 10.1161/CIRCULATIONAHA.109.849539

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

Review 1.  Immune regulation by phospholipase C-β isoforms.

Authors:  Wenbin Xiao; Yuko Kawakami; Toshiaki Kawakami
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 2.  New insights into modulation of thrombin formation.

Authors:  Henri M H Spronk; Julian I Borissoff; Hugo ten Cate
Journal:  Curr Atheroscler Rep       Date:  2013-11       Impact factor: 5.113

Review 3.  Regulation of thrombosis and vascular function by protein methionine oxidation.

Authors:  Sean X Gu; Jeff W Stevens; Steven R Lentz
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

4.  Human thrombomodulin knock-in mice reveal differential effects of human thrombomodulin on thrombosis and atherosclerosis.

Authors:  Thomas J Raife; Denis M Dwyre; Jeff W Stevens; Rochelle A Erger; Lorie Leo; Katina M Wilson; Jose A Fernández; Jennifer Wilder; Hyung-Suk Kim; John H Griffin; Nobuyo Maeda; Steven R Lentz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

Review 5.  IP3 receptor signaling and endothelial barrier function.

Authors:  Mitchell Y Sun; Melissa Geyer; Yulia A Komarova
Journal:  Cell Mol Life Sci       Date:  2017-08-12       Impact factor: 9.261

Review 6.  Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models.

Authors:  Sarah L Tressel; Georgios Koukos; Boris Tchernychev; Suzanne L Jacques; Lidija Covic; Athan Kuliopulos
Journal:  Methods Mol Biol       Date:  2011

7.  Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes.

Authors:  Thati Madhusudhan; Hongjie Wang; Beate K Straub; Elisabeth Gröne; Qianxing Zhou; Khurrum Shahzad; Sandra Müller-Krebs; Vedat Schwenger; Bruce Gerlitz; Brian W Grinnell; John H Griffin; Jochen Reiser; Hermann-Josef Gröne; Charles T Esmon; Peter P Nawroth; Berend Isermann
Journal:  Blood       Date:  2011-11-23       Impact factor: 22.113

Review 8.  Phospholipase C-β in immune cells.

Authors:  Toshiaki Kawakami; Wenbin Xiao
Journal:  Adv Biol Regul       Date:  2013-08-14

9.  Countervailing effects on atherogenesis and plaque stability: a paradoxical benefit of hypercoagulability?

Authors:  Jeff W Stevens; Steven R Lentz
Journal:  Circulation       Date:  2009-08-17       Impact factor: 29.690

10.  Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition.

Authors:  Sumra Nazir; Ihsan Gadi; Moh'd Mohanad Al-Dabet; Ahmed Elwakiel; Shrey Kohli; Sanchita Ghosh; Jayakumar Manoharan; Satish Ranjan; Fabian Bock; Ruediger C Braun-Dullaeus; Charles T Esmon; Tobias B Huber; Eric Camerer; Chris Dockendorff; John H Griffin; Berend Isermann; Khurrum Shahzad
Journal:  Blood       Date:  2017-09-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.